261 related articles for article (PubMed ID: 30319132)
1. [Aggressive variants of castration resistant prostate cancer (CRPC): neuroendocrine prostate cancer.].
Quicios-Dorado C; Bolufer-Moragues E; Gomis-Goti C; Cabello-Benavente R; Cannata-Ortiz PJ; González-Enguita C
Arch Esp Urol; 2018 Sep; 71(8):721-734. PubMed ID: 30319132
[TBL] [Abstract][Full Text] [Related]
2. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
[No Abstract] [Full Text] [Related]
3. Emerging Variants of Castration-Resistant Prostate Cancer.
Vlachostergios PJ; Puca L; Beltran H
Curr Oncol Rep; 2017 May; 19(5):32. PubMed ID: 28361223
[TBL] [Abstract][Full Text] [Related]
4.
Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.
Puca L; Vlachostergios PJ; Beltran H
Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29844220
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and management of neuroendocrine prostate cancer.
de Kouchkovsky I; Chan E; Schloss C; Poehlein C; Aggarwal R
Prostate; 2024 Apr; 84(5):426-440. PubMed ID: 38173302
[TBL] [Abstract][Full Text] [Related]
7. The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance.
Hu CY; Wu KY; Lin TY; Chen CC
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008817
[TBL] [Abstract][Full Text] [Related]
8. [Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions].
Campedel L; Kossaï M; Blanc-Durand P; Rouprêt M; Seisen T; Compérat E; Spano JP; Malouf G
Bull Cancer; 2017 Sep; 104(9):789-799. PubMed ID: 28673439
[TBL] [Abstract][Full Text] [Related]
9. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
10. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.
Flores-Morales A; Bergmann TB; Lavallee C; Batth TS; Lin D; Lerdrup M; Friis S; Bartels A; Kristensen G; Krzyzanowska A; Xue H; Fazli L; Hansen KH; Røder MA; Brasso K; Moreira JM; Bjartell A; Wang Y; Olsen JV; Collins CC; Iglesias-Gato D
Clin Cancer Res; 2019 Jan; 25(2):595-608. PubMed ID: 30274982
[TBL] [Abstract][Full Text] [Related]
11. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
DeLucia DC; Cardillo TM; Ang L; Labrecque MP; Zhang A; Hopkins JE; De Sarkar N; Coleman I; da Costa RMG; Corey E; True LD; Haffner MC; Schweizer MT; Morrissey C; Nelson PS; Lee JK
Clin Cancer Res; 2021 Feb; 27(3):759-774. PubMed ID: 33199493
[TBL] [Abstract][Full Text] [Related]
12. Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S; Inoue T; Ogawa O; Gleave ME
Int J Urol; 2018 Apr; 25(4):345-351. PubMed ID: 29396873
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review.
Usmani S; Orevi M; Stefanelli A; Zaniboni A; Gofrit ON; Bnà C; Illuminati S; Lojacono G; Noventa S; Savelli G
Crit Rev Oncol Hematol; 2019 Jun; 138():29-37. PubMed ID: 31092382
[TBL] [Abstract][Full Text] [Related]
14. Addressing the need for more therapeutic options in neuroendocrine prostate cancer.
Kemble J; Kwon ED; Karnes RJ
Expert Rev Anticancer Ther; 2023 Feb; 23(2):177-185. PubMed ID: 36698089
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
Beltran H; Oromendia C; Danila DC; Montgomery B; Hoimes C; Szmulewitz RZ; Vaishampayan U; Armstrong AJ; Stein M; Pinski J; Mosquera JM; Sailer V; Bareja R; Romanel A; Gumpeni N; Sboner A; Dardenne E; Puca L; Prandi D; Rubin MA; Scher HI; Rickman DS; Demichelis F; Nanus DM; Ballman KV; Tagawa ST
Clin Cancer Res; 2019 Jan; 25(1):43-51. PubMed ID: 30232224
[TBL] [Abstract][Full Text] [Related]
16. Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients.
Bhagirath D; Liston M; Akoto T; Lui B; Bensing BA; Sharma A; Saini S
Sci Rep; 2021 Apr; 11(1):8279. PubMed ID: 33859239
[TBL] [Abstract][Full Text] [Related]
17. Reprint of: de novo neuroendocrine features in prostate cancer.
Abdulfatah E; Fine SW; Lotan TL; Mehra R
Hum Pathol; 2023 Mar; 133():115-125. PubMed ID: 36894369
[TBL] [Abstract][Full Text] [Related]
18. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.
Lin D; Dong X; Wang K; Wyatt AW; Crea F; Xue H; Wang Y; Wu R; Bell RH; Haegert A; Brahmbhatt S; Hurtado-Coll A; Gout PW; Fazli L; Gleave ME; Collins CC; Wang Y
Oncotarget; 2015 Jan; 6(3):1806-20. PubMed ID: 25544761
[TBL] [Abstract][Full Text] [Related]
19. Treatment-induced neuroendocrine prostate cancer and
Wishahi M
World J Clin Cases; 2024 May; 12(13):2143-2146. PubMed ID: 38808339
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
Yamada Y; Beltran H
Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
